Evidence map›Paper›PMID 30890396›Full record

ArticleBioorganic & medicinal chemistry2019

Inhibition of diverse opportunistic viruses by structurally optimized retrograde trafficking inhibitors.

Dhimant Desai, Matthew Lauver, Alexandria Ostman, Linda Cruz, Kevin Ferguson, Ge Jin, Brianne Roper, Daniel Brosius, Aron Lukacher, Shantu Amin and 1 more

Abstract read
In one paragraph

Article in Bioorganic & medicinal chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Molecules (Basel, Switzerland) · 2024
    Review
  3. Article
  4. Antiviral Agents - Benzazine Derivatives.Chemistry of heterocyclic compounds · 2021
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Dhimant DesaiDepartment of Pharmacology, Penn State College of Medicine, 500 University Drive, Hershey, PA 17033, United States.
Matthew LauverDepartment of Microbiology & Immunology, Penn State College of Medicine, 500 University Drive, Hershey, PA 17033, United States.
Alexandria OstmanDepartment of Microbiology & Immunology, Penn State College of Medicine, 500 University Drive, Hershey, PA 17033, United States.
Linda CruzDepartment of Microbiology & Immunology, Penn State College of Medicine, 500 University Drive, Hershey, PA 17033, United States.
Kevin FergusonDepartment of Microbiology & Immunology, Penn State College of Medicine, 500 University Drive, Hershey, PA 17033, United States.
Ge JinDepartment of Microbiology & Immunology, Penn State College of Medicine, 500 University Drive, Hershey, PA 17033, United States.
Brianne RoperDepartment of Microbiology & Immunology, Penn State College of Medicine, 500 University Drive, Hershey, PA 17033, United States.
Daniel BrosiusDepartment of Pharmacology, Penn State College of Medicine, 500 University Drive, Hershey, PA 17033, United States.
Aron LukacherDepartment of Microbiology & Immunology, Penn State College of Medicine, 500 University Drive, Hershey, PA 17033, United States.
Shantu AminDepartment of Pharmacology, Penn State College of Medicine, 500 University Drive, Hershey, PA 17033, United States.
Nick BuchkovichDepartment of Microbiology & Immunology, Penn State College of Medicine, 500 University Drive, Hershey, PA 17033, United States. Electronic address: njb963@psu.edu.

Funding

A Mouse Model to Define Immunovirologic Determinants of Polyomavirus CNS DiseaseR01NS088367 · NINDS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI LUKACHER, ARON ELIOT · 2014 to 2021
$2.8M
Pathogenesis of Mouse Polyomavirus-associated CNS DemyelinationR01NS092662 · NINDS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI LUKACHER, ARON ELIOT · 2016 to 2022
$2.1M
NINDS NIH HHS R01 NS088367NINDS NIH HHS R01 NS092662
6 · The paper itself

Abstract

Opportunistic viruses are a major problem for immunosuppressed individuals, particularly following organ or stem cell transplantation. Current treatments are non-existent or suffer from problems such as high toxicity or development of resistant strains. We previously published that a trafficking inhibitor that targets a host protein greatly reduces the replication of human cytomegalovirus. This inhibitor was also shown to be moderately effective against polyomaviruses, another family of opportunistic viruses. We have developed a panel of analogues for this inhibitor and have shown that these analogues maintain their high efficacy against HCMV, while substantially lowering the concentration required to inhibit polyomavirus replication. By targeting a host protein these compounds are able to inhibit the replication of two very different viruses. These observations open up the possibility of pan-viral inhibitors for immunosuppressed individuals that are effective against multiple, diverse opportunistic viruses.

Indexed as

AnimalsAntiviral AgentsCell LineCell SurvivalCytomegalovirusHumansMicePolyomavirusQuinazolinonesVirus ReplicationAntiviral AgentsQuinazolinonesAntiviralsHuman cytomegalovirusMouse polyomavirusRetrograde traffickingSyntaxin 5

Identifiers

PMID30890396
PMCPMC7050290

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.